N-acetyl cysteine + alpha lipoic acid + liposomal glutathione + T900607-sodium

This entry describes a combination of the antioxidant supplements N-acetyl cysteine (NAC), alpha lipoic acid (ALA), and liposomal glutathione, alongside the experimental antineoplastic agent T900607-sodium. T900607-sodium is a synthetic pentafluorophenylsulfonamide developed by Tularik (later acquired by Amgen) that acts as a tubulin-binding agent. It binds irreversibly to the colchicine-binding site on beta-tubulin, inhibiting microtubule polymerization and inducing G2/M cell cycle arrest and apoptosis. The antioxidants NAC, ALA, and glutathione are often associated with T900607 in research contexts because the drug's cytotoxicity is modulated by intracellular glutathione levels; T900607 is a substrate for the multidrug resistance-associated protein (MRP1), and its efficacy can be influenced by the cellular redox state. T900607-sodium was evaluated in Phase 2 clinical trials for non-Hodgkin's lymphoma (NHL) and other solid tumors, but clinical development was discontinued in the mid-2000s.

Other names

N-(3-((aminocarbonyl)amino)-4-methoxyphenyl)-2,3,4,5,6-pentafluorobenzenesulfonamide sodium saltTularik NHL drug